(11beta,16alpha)-9-Fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl acetate hydrate (1:1)(CAS: 55812-90-3)

This compound is a hydrate and crystalline in form. It has a molecular weight of approximately 517.61 g/mol. It is poorly soluble in water but soluble in organic solvents like ethanol and methanol. Chemically, it reacts readily with bases and has a relatively low reactivity towards acids. It is stable in the absence of moisture and light.

This compound is typically synthesized via a multi-step process involving the reduction of a fluoro-pregnanone, followed by acetylation and hydration. The synthesis involves the use of a palladium catalyst for the reduction step, ensuring high selectivity and yield. The final step involves the addition of acetic acid and water to form the hydrate.

This compound is primarily used in the pharmaceutical industry due to its hormonal properties. It is also of interest in the research and development of new drug candidates for various endocrine-related disorders. Its unique chemical structure makes it valuable in the synthesis of progestogens and other hormonal drugs.

Handling this compound requires the use of personal protective equipment (PPE) such as gloves and safety goggles. It should be conducted in a well-ventilated area or a fume hood to prevent inhalation. Spills should be managed carefully, and the material safety data sheet (MSDS) should be consulted for specific spill procedures. The compound is stable under normal conditions but should be stored away from moisture and light.